Skip to main content
SpringerLink
Log in

New antineoplastic agents in lung cancer 1988–1993

  • Chapter
Lung Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 72))

Abstract

Chemotherapy is the standard initial treatment for patients with small cell lung cancer (SCLC), and combination chemotherapy can prolong the lives of patients with non-small cell lung cancer (NSCLC) [1,2]. Despite these developments, most patients develop metastatic disease, and lung cancer remains the leading cause of death from cancer [3]. Over the past five years, a number of new agents with activity against lung cancer have been identified, offering the potential for improved control of this disease. A number of these drugs have novel mechanisms of action. Additionally, the understanding of the pharmacokinetics of ‘older’ agents has expanded, resulting in the more effective use of the available chemotherapeutic drugs. At the same time, we have also learned that many new agents have insufficient antitumor activity against lung cancer to warrant further development. Agents identified between 1988 and 1993 with potential usefulness in lung cancer patients are presented in table 1 and discussed in detail below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rapp E, Pater JL, Willan A, et al. 1988. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641.

    PubMed  CAS  Google Scholar 

  2. Dillman R, Seagren S, Propert K, et al. 1990. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940–945.

    Article  PubMed  CAS  Google Scholar 

  3. Boring C, Squires T, Tong T. 1993. Cancer statistics, 1993. CA C ancer J Clin 43(1):7–26.

    Article  CAS  Google Scholar 

  4. Rigas JR, Kris MG, Tong W, et al. 1991. Phase I trial of chloroquinoxaline sulfonamide (CQS): A unique agent with activity in NSCLC stem cell assay (abstract). Lung Cancer 7(Suppl):108.

    Google Scholar 

  5. Carey R, Comis R, Anbar D, et al. 1983. Cancer and leukemia group B phase II non-small cell lung carcinoma trial: axiridinylbenzoquinone (AZQ). Cancer Treat Rep 67(1):95–96.

    PubMed  CAS  Google Scholar 

  6. Chabner BA. 1992. Camptothecins (editorial). J Clin Oncol 10(1):3–4.

    PubMed  CAS  Google Scholar 

  7. Hertzberg RP, Holden KG, Hecht SM, et al. 1987. Characterization of structural features of camptothecin essential for topoisomerase I interaction and for induction of protein-linked DNA breaks in cells (abstract). Proc Am Assoc Cancer Res 28:7.

    Google Scholar 

  8. Maxwell A, Geliert M. 1986. Mechanistic aspects of DNA topoisomerases. Adv Protein Chera 38:69–107.

    Article  CAS  Google Scholar 

  9. Kunimoto T, Nitta K, Tanaka T, et al. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidion)-1-piperidion [arbonyloxy-camptothecin, anovelwater-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944–5947.

    PubMed  CAS  Google Scholar 

  10. Matsuzaki T, Yokokura T, Mutai M. 1988. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308–312.

    Article  PubMed  CAS  Google Scholar 

  11. Negoro S, Masahiro F, Masuda N, et al. 1991. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 83(16):1164–1168.

    Article  PubMed  CAS  Google Scholar 

  12. Fukuoka M, Niitani H, Suzuki A, et al. 1992. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16–20.

    PubMed  CAS  Google Scholar 

  13. WHO Handbook for Reporting Results of Cancer Treatment. 1979. World Health Organization: Geneva.

    Google Scholar 

  14. Takada M, Fukuoka M, Kudoh S, et al. 1992. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice (abstract). Proc Am Assoc Cancer Res 33:226.

    Google Scholar 

  15. Negoro S, Fukuoka M, Niitani H, et al. 1991. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:241.

    Google Scholar 

  16. Fukuoka M, Takada M, Nakagawa K, et al. 1992. CPT-11 dose in combination with cisplatin for advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 11:293.

    Google Scholar 

  17. Bissett D, Setanoians A, Cassidy J, et al. 1993. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion (abstract). Cancer Res 53:523–527.

    PubMed  CAS  Google Scholar 

  18. Bissery M, Guernard D, Gueritte-Voegelin F, et al. 1991. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845–4852.

    PubMed  CAS  Google Scholar 

  19. Jassem J, Karnicka-Miodkowska H, van Pottelsberghe C, et al. 1992. EORTC phase II study of navelbine (NVB) in previously treated patients (PT) with small cell lung carcinoma (SCLC). Proc Am Soc Clin Oncol 11:309.

    Google Scholar 

  20. Extra J, Rousseau F, Bruno R, et al. 1993. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion (abstract). Cancer Res 53:1037–1042.

    PubMed  CAS  Google Scholar 

  21. Pazdur R, Newman RA, Newman BM, et al. 1992. Phase I trial of taxotere: Five-day schedule. J Natl Cancer Society 84(23):1781–1788.

    Article  CAS  Google Scholar 

  22. Vandenberg T, Pritchard KI, Eisenhauer E. 1992. Phase II study of weekly 10-EDAM (Edatrexate) as first line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study (abstract). Proc Am Soc Clin Oncol 11:51.

    Google Scholar 

  23. Burris H, Eckardt J, Fields S, et al. 1993. Phase II trials of taxotere in patients with non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 12:335.

    Google Scholar 

  24. Cerny T, Wanders J, Kaplan S, et al. 1993. Taxotere is an active drug in non small cell lung (NSCLC) cancer: A phase II trial of the early clinical trials group (ECTG) (abstract). Proc Am Soc Clin Oncol 12:331.

    Google Scholar 

  25. Rigas JR, Francis PA, Kris MG, et al. 1993. Phase II trial of taxotere in non-small lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 12:336.

    Google Scholar 

  26. Rumberger BG, Barrueco JR, Sirotnak FM. 1990. Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res 50:4639–4643.

    PubMed  CAS  Google Scholar 

  27. Sirotnak FM, DeGraw JI, Moccio DM, et al. 1984. New folate analogues of the 10-deaza-aminopterin series; basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12:18–25.

    PubMed  CAS  Google Scholar 

  28. Samuels LL, M MD, M SF. 1985. Similar differential for total polyglutamylation and cytotoxicity among various folate analogs in human and murine tumor cells in vitro. Cancer Res 45:1488–1495.

    PubMed  CAS  Google Scholar 

  29. Schmid FA, Sirotnak FM, Otter GM. 1985. New folate analogs of the 10-deaza-aminopterin series. Markedly increased activity of the 10-ethyl analogue compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69:551–553.

    PubMed  CAS  Google Scholar 

  30. Braakhuis BJM, van Dongen GAMS, Bagnay MBS, et al. 1989. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Chemother Head Neck Cancer Xenogr (November/December):511–515.

    Google Scholar 

  31. Brown DH, Braakhuis BJM, Van Dongen GAMS, et al. 1989. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts. Anticancer Res 9:1549–1552.

    PubMed  CAS  Google Scholar 

  32. Kris M, Kinahan J, Gralla R, et al. 1988. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res 48:5573–5579.

    PubMed  CAS  Google Scholar 

  33. Shum K, Kris M, Gralla R, et al. 1988. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 6(3):446–450.

    PubMed  CAS  Google Scholar 

  34. Lee JS, Libshitz HI, Murphy WK, et al. 1990. Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIb or IV non-small cell lung cancer. Invest New Drugs 8:299–304.

    Article  PubMed  CAS  Google Scholar 

  35. Souhami R, Hartley J, Allen R, et al. 1991. 10-EDAM (10-Ethyl-10-Deazaaminopterin) in untreated advanced non small cell lung cancer (SCLC) (abstract). Lung Cancer 7(Suppl): 134.

    Google Scholar 

  36. Schmid FA, Sirotnak FM, Otter GM, et al. 1987. Combination chemotherapy with a new folate analog: Activity of 10-ethyl-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Cancer Treat Rep 71:727–732.

    PubMed  CAS  Google Scholar 

  37. Sirotnak FM, Schmid FA, I DJ. 1989. Intracavitary therapy of murine ovarian cancer with cis-Diamminedichloroplatinum (II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection (abstract). Cancer Res 49:2890–2893.

    PubMed  CAS  Google Scholar 

  38. Kris MG, Gralla RJ, Potanovich LM, et al. 1990. Assessment of pretreatment symptoms and improvement after EDAM+mitomycin+vinblastine in patients with inoperable non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 9:229.

    Google Scholar 

  39. Lee JS, Libshitz HI, Murphy WK, et al. 1990. Phase II trial of 10-ethyl-10-deaza-aminopterin (10-edam) with cytoxan (CTX) and cisplatin (CDDP) for stage IIIB/IV non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 9:241.

    Google Scholar 

  40. Lee JS, Libshitz H, Fossella F, et al. 1992. Brief communication. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small cell lung cancer. J Natl Cancer Inst 84:1039–1040.

    Article  PubMed  CAS  Google Scholar 

  41. Wiesenfeld M, Su J, Jett J. 1992. Phase II study of edatrexate (10-EDAM) in patients with small cell carcinoma (SCC) of the lung (abstract). Proc Am Soc Clin Oncol 11:311.

    Google Scholar 

  42. Casazza A, DiMarco A, Bertazzoli C. 1978. Antitumor activity, toxicity, and pharmacological properties of 4′-epiadriamycin. In Current Chemotherapy, W Siegenthaler and R Luthy (eds.). American Society of Microbiology; Washington, DC, pp. 1257–1260.

    Google Scholar 

  43. Casazza A. 1979. Experimental evaluation of anthracycline analogues. Cancer Treat Rep 63:835–844.

    PubMed  CAS  Google Scholar 

  44. Zbinden G, Brandie E. 1975. Toxicologic screening of daunorubicin (NSC-82151) and their derivatives in rats. Cancer Chemother Rep 59:707–715.

    PubMed  CAS  Google Scholar 

  45. Feld R, Wierzbicki R, Walde PLD, et al. 1992. Phase I–II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol 10(2):297–303.

    PubMed  CAS  Google Scholar 

  46. Joss R, Hansen H, Hansen M, et al. 1984. Phase II trial of epirubicin in advanced squamous, adenocarcinoma and large cell carcinoma of the lung. Eur J Cancer Oncol 20:495–499.

    Article  CAS  Google Scholar 

  47. Kaiman L, Kris M, Gralla R, et al. 1983. Phase II trial of 4′-epi-doxorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 67(6):591–592.

    Google Scholar 

  48. Martoni A, Melotti B, Guaraldi M, et al. 1990. Activity of high dose epirubicin (HD EPI) in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 9:237.

    Google Scholar 

  49. Blackstein M, Eisenhauer EA, Wierzbicki R, et al. 1990. Epirubicin in extensive small-cell lung cancer: A phase II study in previously untreated patients: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 8:385–389.

    PubMed  CAS  Google Scholar 

  50. Eckhardt S, Kolaric K, Vukas D, et al. 1990. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. Med Oncol Tumor Pharmacother 7(1):19–23.

    PubMed  CAS  Google Scholar 

  51. Macchiarini P, Danesi R, Mariotti R, et al. 1990. Phase II study of high-dose epirubicin in untreated patients with small-cell lung cancer. Am J Clin Oncol 13(4):302–307.

    Article  PubMed  CAS  Google Scholar 

  52. Slevin ML, Clark PI, Joel SP, et al. 1989. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333–1340.

    PubMed  CAS  Google Scholar 

  53. Waits TM, Johnson DH, Hainsworth JD, et al. 1992. Prolonged administration of oral etoposide in non-small-cell lung cancer: A phase II trial. J Clin Oncol 10(2):292–296.

    PubMed  CAS  Google Scholar 

  54. Estape J, Palombo H, Sanchez-Lloret J, et al. 1992. Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 28A(4/5):835–837.

    Article  PubMed  CAS  Google Scholar 

  55. Grant SC, Gralla RJ, Kris MG, et al. 1992. Single agent chemotherapy trials in small-cell lung cancer, 1970–1990. The case for studies in previously treated patients. J Clin Oncol 10(3):484–498.

    PubMed  CAS  Google Scholar 

  56. Itri LM, Gralla RJ. 1982. A review of etoposide in patients with non-small cell lung cancer (NSCLC). Cancer Treat Rev 9:115–118.

    Article  PubMed  Google Scholar 

  57. Saxman S, Loehrer Sr. PJ, Logie K, et al. 1991. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer (abstract). Invest New Drugs 9:253–256.

    Article  PubMed  CAS  Google Scholar 

  58. Clark P, Cottier B, Joel S, et al. 1990. Prolonged administration of single-agent oral etoposide in patients with untreated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 9:226.

    Google Scholar 

  59. Johnson DH, Greco FA, Strupp J, et al. 1990. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8(10):1613–1617.

    PubMed  CAS  Google Scholar 

  60. Clark P, Cottier B, Joel S, et al. 1991. Two prolonged schedules of single-agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10:268.

    Google Scholar 

  61. Murphy PB, Hainsworth JD, Greco FA, et al. 1992. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer 69:370–375.

    Article  PubMed  CAS  Google Scholar 

  62. Fukuda M, Nakano S, Fukuoka M, et al. 1991. Chronic daily administration of oral etoposide and cisplatin for advanced non-small cell lung cancer (NSCLC) (abstract). Lung Cancer 7(Suppl):118.

    Google Scholar 

  63. Monnier A, Pujol JL, Cerinna ML, et al. 1991. Fotemustine: French multicenter phase II study in 67 patients with advanced non small cell lung carcinoma (NSCLC) (abstract). Lung Cancer 7(Suppl): 119.

    Article  Google Scholar 

  64. Riviere A, Le Cesne A, Benoliel C, et al. 1991. Phase II pilot study of fotemustine-cisplatin combination in 24 patients with advanced non small cell lung carcinoma (abstract). Lung Cancer 7(Suppl): 119.

    Article  Google Scholar 

  65. Hertel L, Boder G, Kroin J, et al. 1990. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417–4422.

    PubMed  CAS  Google Scholar 

  66. Abbruzzese J, Grunewald R, Weeks E, et al. 1991. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 90(3):491–498.

    Google Scholar 

  67. Lund B, Anderson H, Walling J, et al. 1991. Phase II study of gemcitabine in non small cell lung cancer (NSCLC) (abstract). Lung Cancer 7(Suppl):121.

    Google Scholar 

  68. Lund B, Ryberg M, Anderson H, et al. 1992. A phase II study of gemcitabine in non-small cell lung cancer (NSCLC) using a twice weekly schedule (abstract). Proc Am Assoc Cancer Res 33:226.

    Google Scholar 

  69. Abratt R, Bezwoda W, Falkson G, et al. 1992. Efficacy and safety of gemcitabine in non-small cell lung cancer-Phase II study results (abstract). Proc Am Soc Clin Oncol 11:311.

    Google Scholar 

  70. Eisenhauer E, Cormier Y, Gregg R, et al. 1992. Gemcitabine is active in patients (PTS) with previously untreated extensive small cell lung cancer (SCLC) — A phase II study of the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) (abstract). Proc Am Soc Clin Oncol 11:309.

    Google Scholar 

  71. Rowinsky E, McGuire W. 1992. Taxol: Present status and future prospects. Contemp Oncol (March):29–36.

    Google Scholar 

  72. Schiff PB, Fant J, Horwitz SB. 1979. Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667.

    Article  PubMed  CAS  Google Scholar 

  73. Schiff PB, Horwitz SB. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565.

    Article  PubMed  CAS  Google Scholar 

  74. Parness J, Horwitz SB. 1981. Taxol binds to polymerized microtubules in vitro. J Cell Biol 91:479.

    Article  PubMed  CAS  Google Scholar 

  75. Fuchs DA, Johnson RK. 1978. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 62:1219.

    PubMed  CAS  Google Scholar 

  76. Rowinsky EK, Donehower RC, Jones RJ. 1988. Microtubule changes and cytotoxicity in leukemic cells treated with taxol. Cancer Res 48:4093–4100.

    PubMed  CAS  Google Scholar 

  77. Kris M, O’Connell J, Gralla R, et al. 1986. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70(5):605–607.

    PubMed  CAS  Google Scholar 

  78. Brown T, Havlin G, Weiss G, et al. 1991. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9(7): 1261–1267.

    PubMed  CAS  Google Scholar 

  79. Wiernik P, Schwartz E, Einzig A, et al. 1987. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5(8): 1232–1239.

    PubMed  CAS  Google Scholar 

  80. Rowinsky E, Burke P, Karp J, et al. 1989. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49:4640–4647.

    PubMed  CAS  Google Scholar 

  81. Rowinsky EK, Cazenave LA, Donehower RC. 1990. Taxol: A novel investigational an-timicrotubule agent. J Natl Cancer Inst 82(15):1247–1259.

    Article  PubMed  CAS  Google Scholar 

  82. Weiss R, Donehower R, Wiernik P, et al. 1990. Hypersensitivity reactions from taxol. Am J Clin Oncol 8:1263–1268.

    CAS  Google Scholar 

  83. Donehower RC, Rowinsky EK, Grochow LB, et al. 1987. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71:1171–1177.

    PubMed  CAS  Google Scholar 

  84. Rowinsky E, Gilbert M, McGuire W, et al. 1991. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9(9):1692–1703.

    PubMed  CAS  Google Scholar 

  85. Chang AY, Kim K, Glick J, et al. 1993. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85(5):388–394.

    Article  PubMed  CAS  Google Scholar 

  86. Murphy WK, Fossella FV, Winn RJ, et al. 1993. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85(5):384–388.

    Article  PubMed  CAS  Google Scholar 

  87. Spremulli E, Schulz JJ, Speckhart VJ, et al. 1980. Phase II study of VM-26 in adult malignancies. Cancer Treat Rep 64(1): 147–149.

    PubMed  CAS  Google Scholar 

  88. Samson MK, Baker LH, Talley RW, et al. 1978. VM-26: A clinical study in advanced carcinoma of the lung and ovary. Eur J Cancer 14:1395–1399.

    Article  PubMed  CAS  Google Scholar 

  89. Creech RH, Mehta CR, Cohen M, et al. 1981. Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma. Cancer Treat Rep 65(5–6):431–438.

    PubMed  CAS  Google Scholar 

  90. Giaccone G, Donadio M, Ferrati P, et al. 1987. Teniposide in the treatment on non-small cell lung carcinoma. Cancer Treat Rep 71(1):83–85.

    PubMed  CAS  Google Scholar 

  91. Bork E, Ersbøll J, Dombernowsky P, et al. 1991. Teniposide and etoposide in previously untreated small-cell lung cancer: A randomized study. J Clin Oncol 9:1627–1631.

    PubMed  CAS  Google Scholar 

  92. Depierre A, Lemaire E, Dabouis G, et al. 1991. A phase II study of navelbine (Vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14(2):115–119.

    Article  PubMed  CAS  Google Scholar 

  93. Besenval M, Delgado M, Demarez JP, et al. 1989. Safety and tolerance of navelbine in phase I–II clinical studies. Semin Oncol 16(2)(Suppl 4):37–40.

    PubMed  CAS  Google Scholar 

  94. Mathe G, Reizenstein P. 1985. Phase I pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett 27:285–293.

    Article  PubMed  CAS  Google Scholar 

  95. Kubotal K, Furusel K, Niitani H: 1991. A late phase II study of navelbine (vinorelbine), a new vinca alkaloid derivative, in non small cell lung cancer (abstract). Lung Cancer 7(Suppl):117.

    Article  Google Scholar 

  96. Berthaud P, Le Chevalier T, Ruffle P, et al. 1992. Phase I–II study of vinorelbine (Navelbine.113) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 28A(11):1863–1865.

    Article  PubMed  CAS  Google Scholar 

  97. Jones AL, Davies C, Smith IE. 1991. Phase II study of zeniplatin, an active new agent in advanced non-small cell lung cancer (NSCLC) (abstract). Lung Cancer 7(Suppl):125.

    Google Scholar 

Download references

Authors
  1. Stefan C. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark G. Kris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology 5074, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Heine H. Hansen

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Grant, S.C., Kris, M.G. (1994). New antineoplastic agents in lung cancer 1988–1993. In: Hansen, H.H. (eds) Lung Cancer. Cancer Treatment and Research, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2630-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2630-8_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6128-2

  • Online ISBN: 978-1-4615-2630-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation